Equities Analysts Issue Forecasts for VKTX Q4 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Analysts at HC Wainwright issued their Q4 2026 EPS estimates for shares of Viking Therapeutics in a report released on Thursday, February 12th. HC Wainwright analyst J. Pantginis expects that the biotechnology company will earn ($0.81) per share for the quarter. The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, February 11th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.49). During the same quarter in the previous year, the company earned ($0.32) EPS.

Other equities analysts have also recently issued research reports about the company. Zacks Research cut Viking Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. Morgan Stanley reaffirmed an “overweight” rating and set a $99.00 price objective on shares of Viking Therapeutics in a research note on Thursday. JPMorgan Chase & Co. reduced their target price on shares of Viking Therapeutics from $80.00 to $75.00 and set an “overweight” rating on the stock in a research note on Friday, October 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a report on Wednesday, January 21st. Finally, Canaccord Genuity Group upped their price target on shares of Viking Therapeutics from $106.00 to $107.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Viking Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $87.80.

Viking Therapeutics Price Performance

Shares of VKTX stock opened at $30.49 on Friday. The company has a market cap of $3.45 billion, a PE ratio of -9.59 and a beta of 0.75. Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $43.15. The stock’s 50 day simple moving average is $33.33 and its two-hundred day simple moving average is $32.61.

Insiders Place Their Bets

In other news, CEO Brian Lian sold 233,409 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $32.96, for a total transaction of $7,693,160.64. Following the sale, the chief executive officer owned 2,499,291 shares in the company, valued at approximately $82,376,631.36. The trade was a 8.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Marianna Mancini sold 57,661 shares of the company’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $32.98, for a total transaction of $1,901,659.78. Following the transaction, the chief operating officer owned 409,190 shares in the company, valued at approximately $13,495,086.20. This trade represents a 12.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 364,731 shares of company stock worth $12,053,627 over the last quarter. Company insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Norges Bank acquired a new stake in shares of Viking Therapeutics during the second quarter worth $46,846,000. BNP Paribas Financial Markets raised its stake in Viking Therapeutics by 536.3% in the 4th quarter. BNP Paribas Financial Markets now owns 992,695 shares of the biotechnology company’s stock worth $34,923,000 after acquiring an additional 836,686 shares during the last quarter. Two Sigma Investments LP lifted its position in Viking Therapeutics by 58.7% during the 3rd quarter. Two Sigma Investments LP now owns 2,085,487 shares of the biotechnology company’s stock worth $54,807,000 after acquiring an additional 771,704 shares during the period. Ameriprise Financial Inc. lifted its position in Viking Therapeutics by 41.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,092,840 shares of the biotechnology company’s stock worth $55,000,000 after acquiring an additional 616,526 shares during the period. Finally, Cubist Systematic Strategies LLC grew its stake in Viking Therapeutics by 6,315.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 596,650 shares of the biotechnology company’s stock valued at $15,811,000 after purchasing an additional 587,350 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Viking Therapeutics News Roundup

Here are the key news stories impacting Viking Therapeutics this week:

• Positive Sentiment: Company will advance oral VK2735 into a late‑stage (Phase 3) obesity program, targeting a 3Q26 start — a key development milestone that materially derisks the asset and increases potential commercial value. Viking Therapeutics plans to advance oral obesity drug to late-stage trial
• Positive Sentiment: Subcutaneous VK2735 VANQUISH program is progressing (VANQUISH‑1 enrollment complete; VANQUISH‑2 nearing full enrollment) and a VK2735 maintenance dosing study is fully enrolled with data expected in 3Q26 — multiple near‑term readouts that could drive valuation upside. Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Company ended the quarter with a strong cash balance (~$706M) and plans an IND filing this quarter for a novel amylin agonist — provides runway to fund multiple programs and supports follow‑on development. Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
• Neutral Sentiment: Company outlined dual Phase 3 obesity programs and maintenance regimens in investor materials — strategy clarifies the development path but execution and readouts still lie ahead. Viking Therapeutics outlines dual Phase III obesity programs while advancing oral VK2735 and maintenance regimens
• Neutral Sentiment: Earnings call transcript and management commentary are available; they reiterate program timelines and funding plans — useful for modeling but not immediate catalysts beyond the pipeline news. Viking Therapeutics, Inc. (VKTX) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Viking reported a wider‑than‑expected Q4 loss (EPS of ($1.38) vs. consensus ($0.89)), increasing near‑term cash burn and highlighting that commercial value depends on successful clinical progression. VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.